Physician profile
David Carl Gregory
NPI 1871599522
$3,603.11
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,033 · 2020: $720 · 2021: $1,562 · 2022: $288.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Preventric Diagnostics, INC. | $709.96 | 2021 | |
| Glaxosmithkline, LLC. | $598.71 | 2019-2021 | |
| Pfizer INC. | $375.06 | 2019-2021 | |
| Alkermes, INC. | $295.13 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $199.71 | 2020-2022 | |
| Abbott Laboratories | $179.50 | 2021 | |
| Novo Nordisk INC | $174.77 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $170.81 | 2020-2022 | |
| Abbvie INC. | $131.81 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $118.81 | 2021-2022 | |
| Gilead Sciences, INC. | $114.81 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $73.57 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $63.26 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $60.23 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $56.21 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $56.00 | 2020 | |
| Shire North American Group INC | $41.63 | 2019 | |
| Sanofi-Aventis U.S. LLC | $32.81 | 2021 | |
| Amgen INC. | $28.11 | 2019 | |
| Allergan, INC. | $24.38 | 2019 | |
| Phadia US INC. | $22.04 | 2022 | |
| Sanofi Pasteur INC. | $19.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.38 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $19.32 | 2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $17.12 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Gregory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.